Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.

Huo, Ran; Li, Jinghua; Li, Xiaofang; Shi, Junping; Wang, Kunjie; Jiao, Jin; Shang, Yanhong

Huo, Ran; Li, Jinghua; Li, Xiaofang; Shi, Junping; Wang, Kunjie; Jiao, Jin; Shang, Yanhong.

Affiliation

Huo R; Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China.
Li J; Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China.
Li X; Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China.
Shi J; OrigiMed, Shanghai, People's Republic of China.
Wang K; Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China.
Jiao J; Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China.
Shang Y; Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, People's Republic of China.

Oncologist ; 25(10): 826-832, 2020 10.

Article in En | MEDLINE | ID: mdl-32367600

Subject(s)

Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Acrylamides; Adult; Aniline Compounds; Carcinoma, Adenosquamous/drug therapy; Carcinoma, Adenosquamous/genetics; ErbB Receptors/genetics; Germ Cells; Germ-Line Mutation; Humans; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Male; Mutation; Protein Kinase Inhibitors/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Adenosquamous / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Adult / Humans / Male Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2020 Type: Article

Fulltext

XML

PubMed Links

Search on Google